广州赛隽生物科技

Saijun Biotech is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative cell therapies. The company focuses on mesenchymal stem cells (MSCs) and exosome-based technologies to treat life-threatening and chronic diseases, including liver failure and autoimmune disorders. Its lead candidate, CG-001, is an umbilical cord-derived MSC therapy currently undergoing clinical trials for indications such as acute-on-chronic liver failure. Saijun Biotech leverages its proprietary cell processing and quality control platforms to ensure the safety and efficacy of its regenerative medicine products. The company operates a GMP-compliant manufacturing facility to support its clinical pipeline and future commercialization efforts. Backed by investors like Legend Capital, Saijun Biotech is a key player in China's growing regenerative medicine sector.